Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Zhiteng MaThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-4385-4247
Riley KahanDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0009-0002-7777-4226
Jianping XiaThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0001-9902-0228
Mengxi WuThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-0086-5349
Brandon LuDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.ORCID 0009-0003-6438-4074
Emeraghi DavidDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Ye HeThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0001-7363-1063
Ying ChenThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0009-0000-4812-7658
Jessica F LiuDepartment of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-2663-8438
Mingyuan LiuElectrical and Computer Engineering Department, Duke University, Durham, NC 27708, USA.
Haojun XuThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-5395-3417
Linda StemporaDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-5285-0766
Nader AbrahamDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Ruoyu ZhongThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-0433-0923
Kaichun YangThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0009-0003-6666-4619
Ke JinThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-9225-6470
Ke LiThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-0243-1811
Min ZhangDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Qian WuThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-4252-1109
Andrew BarbasDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0003-3476-2313
Jean KwunDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-8563-5472
Luke P LeeHarvard Medical School, Harvard University; Renal Division and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-1436-4054
Tony Jun HuangThomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-1205-3313
Eileen T ChambersDuke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Funding
The Risks and Opportunities of Homeostatic RepopulationU19AI131471 · NIAID · DUKE UNIVERSITY · PI Xunrong Luo · 2017 to 2026
$30.4M
Enabling Efficient, Fast, Biocompatible Exosome Separation via AcoustofluidicsR01GM132603 · NIGMS · DUKE UNIVERSITY · PI HUANG, TONY JUN · 2019 to 2022
$1.7M
An Acoustofluidic Device for Biocompatible Platelet SeparationR44HL140800 · NHLBI · ASCENT BIO-NANO TECHNOLOGIES, INC. · PI WANG, LIN · 2021 to 2022
$1.5M
Development of a novel acoustofluidic device for targeted antibody removal in pediatric organ transplant rejectionR21HD102790 · NICHD · DUKE UNIVERSITY · PI CHAMBERS, EILEEN TSAI · 2021 to 2022
Antibody-mediated rejection is a leading cause of allograft failure and mortality in pediatric solid organ transplant recipients. Current apheresis systems require large blood volumes and are primarily designed for adults, making them unsuitable for children and small animals. These systems often indiscriminately remove both harmful and protective antibodies, increasing the risk of complications such as life-threatening infections. To address this critical need, we developed acoustofluidic-based system for targeted antibody removal in transplantation (A-START). A-START is engineered to handle small blood volumes and has demonstrated efficacy in preclinical small animal trials. In a sensitized rodent skin transplantation model, A-START only demands 240 microliters of blood, selectively removing donor-specific alloantibodies (DSAs) while preserving protective antibodies, such as tetanus antibodies. A-START retains ~95% of beneficial antibodies and achieves a 60% improvement in DSA removal compared to conventional methods. These findings highlight the transformative potential of A-START as a promising, reliable, scalable solution for improving outcomes in pediatric transplantation and treating antibody-mediated diseases.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Acoustofluidic system for targeted antibody removal in transplantation: Enabling small-volume therapeutic apheresis. · full record | Socratic